Kayrak Mehmet, Gul Enes Elvin, Kaya Coskun, Solak Yalcin, Turkmen Kultigin, Yazici Raziye, Guney Ibrahim, Altintepe Lutfullah, Turk Suleyman, Ozdemir Kurtulus
Department of Cardiology, Meram School of Medicine, Necmettin Erbakan University , Konya , Turkey.
Blood Press. 2014 Feb;23(1):47-53. doi: 10.3109/08037051.2013.796688. Epub 2013 May 31.
Arterial hypertension is a risk factor affecting graft function in renal transplant recipients (RTRs). In pediatric RTRs, high prevalence of masked and nocturnal hypertension was reported. Most of the RTRs had a history of hypertension and some of them were normotensive at outpatient visits whereas home blood pressure (BP) levels were higher. Masked hypertension (MHT) is defined as a normal office BP but an elevated ambulatory BP. Previous reports have demonstrated the detrimental role of MHT in clinical outcomes in hypertensive patients. However, the true prevalence of MHT in RTRs is yet to be defined.
A total of 113 RTRs (mean age 44 ± 16 years, 72 males, 41 females) with normal office BP (< 140/90 mmHg) were enrolled to the study from the outpatient renal transplantation clinic. Ambulatory BP monitoring (ABPM) was performed in all participants for a 24-h period. Average daytime BP values above 135 mmHg systolic and 85 mmHg diastolic were defined as MHT.
The prevalence of MHT in our cohort was 39% (n = 45). Fasting glucose and C-reactive protein levels were higher in patients with MHT compared with normal BP group (p = 0.02 and p = 0.04, respectively). RTRs with deceased donor type had higher prevalence of MHT than RTRs with living donor (40% vs 19%, p = 0.003). In multivariate analysis, deceased donor type could predict the MHT independent of age, gender, office systolic BP level, diabetes mellitus, serum creatinine, C-reactive protein, and glucose levels (OR = 3.62, 95% CI 1.16-11.31, p = 0.03).
We demonstrated an increased prevalence of MHT in a typical renal transplant cohort. In addition, transplantation from a deceased donor may be a predictor of MHT. The prevalence of MHT may help to explain high rate of cardiovascular events in RTRs. Therefore, routine application of ABPM in RTRs may be plausible, particularly in RTRs with deceased donor type.
动脉高血压是影响肾移植受者(RTR)移植肾功能的一个危险因素。在儿科RTR中,隐匿性高血压和夜间高血压的患病率较高。大多数RTR有高血压病史,其中一些在门诊就诊时血压正常,而家庭血压水平较高。隐匿性高血压(MHT)定义为诊室血压正常但动态血压升高。既往报道已证实MHT在高血压患者临床结局中的有害作用。然而,RTR中MHT的真实患病率尚未明确。
从门诊肾移植诊所招募了113例诊室血压正常(<140/90 mmHg)的RTR(平均年龄44±16岁,男性72例,女性41例)。所有参与者均进行了24小时动态血压监测(ABPM)。收缩压高于135 mmHg且舒张压高于85 mmHg的平均日间血压值定义为MHT。
我们队列中MHT的患病率为39%(n = 45)。与血压正常组相比,MHT患者的空腹血糖和C反应蛋白水平更高(分别为p = 0.02和p = 0.04)。死亡供体类型的RTR中MHT的患病率高于活体供体的RTR(40%对19%,p = 0.003)。在多变量分析中,死亡供体类型可独立于年龄、性别、诊室收缩压水平、糖尿病、血清肌酐、C反应蛋白和血糖水平预测MHT(OR = 3.62,95%CI 1.16 - 11.31,p = 0.03)。
我们证实在一个典型的肾移植队列中MHT患病率增加。此外,来自死亡供体的移植可能是MHT的一个预测因素。MHT的患病率可能有助于解释RTR中心血管事件的高发生率。因此,在RTR中常规应用ABPM可能是合理的,特别是在死亡供体类型的RTR中。